ArticleCureus2026
A Rare Case of Spontaneous Tumor Lysis Syndrome in a Pulmonary Neuroendocrine Tumor.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor lysis syndrome (TLS) is a serious medical condition in which the lysis of tumor cells results in a variety of abnormalities, including elevated uric acid, potassium, and phosphorus, decreased calcium, seizures, arrhythmias, and acute kidney injury (AKI). TLS most often occurs in hematologic cancers and after chemotherapy, whereas cases that arise without chemotherapy are termed spontaneous TLS (STLS). In our case, an 81-year-old female with a past medical history of hypertension and chronic obstructive pulmonary disease (COPD) initially presented to the emergency department for left lower back pain that was later found to have been caused by a bony metastatic lesion secondary to a neuroendocrine tumor of the lung. Her hospital stay was complicated by a worsening AKI that was refractory to fluids and the discontinuation of nephrotoxic medications. A uric acid, urine studies, lactate dehydrogenase, and metabolic panel ruled out other causes of her kidney injury and ruled in a diagnosis of STLS. The patient's condition worsened until she required hemodialysis, which she rejected in favor of comfort care. The patient died 14 days after admission. In conclusion, despite the majority of TLS cases originating from hematologic malignancies and in response to chemotherapy, STLS should be considered in refractory AKI for cancer patients, even when secondary to solid tumors like neuroendocrine tumors of the lung.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.